| Identification | Back Directory | [Name]
tibric acid | [CAS]
37087-94-8 | [Synonyms]
Tibric
CP-18524
tibric acid
2-Chloro-5-[(3α,5α-dimethylpiperidino)sulfonyl]benzoic acid
2-Chloro-5-[[(3R,5S)-3,5-dimethylpiperidino]sulfonyl]benzoic acid
2-Chloro-5-[[(3S,5R)-3,5-dimethylpiperidino]sulfonyl]benzoic acid | [EINECS(EC#)]
253-344-0 | [Molecular Formula]
C14H18ClNO4S | [MDL Number]
MFCD00865752 | [MOL File]
37087-94-8.mol | [Molecular Weight]
331.818 |
| Hazard Information | Back Directory | [Uses]
Tibric acid (CP 18524) has similar effects to those of hypolipidemic agents. Tibric acid has orally active triglyceride-lowering effects. Tibric acid can be used for research of hypertriglyceridemia[1][2]. | [in vivo]
Tibric acid (13-125 mg/kg/d, oral administration, daily for 1 week) reduces serum cholesterol and triglyceride levels in rats[2].
| Animal Model: | Rats[1] | | Dosage: | 13, 25, 125 mg/kg/d | | Administration: | oral administration, daily for 1 week | | Result: | Decreased serum cholesterol and triglyceride levels, but increased total liver content of cholesterol, phospholipids, and triglycerides. |
| [References]
[1] Bielmann P, et al. Dose-response to tibric acid: a new hypolipidemic drug in type IV hyperlipoproteinemia. Clin Pharmacol Ther. 1975 May;17(5):606-11. DOI:10.1002/cpt1975175606
[2] Cayen MN, et al. Effect of tibric acid on hepatic cholesterol synthesis in rats. Lipids. 1977 Aug;12(8):684-8. DOI:10.1007/BF02533766 |
|
| Company Name: |
Leancare Ltd.
|
| Tel: |
+33 962096793 |
| Website: |
www.leancare.co.uk |
|